CliffBio
small molecule

MINIVELLE

ESTRADIOL

Loss of exclusivityJuly 2030latest FDA-listed patent expiry
CompanyNoven Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameMINIVELLE
Active ingredientESTRADIOL
Strength0.025MG/24HR
Dosage formFILM, EXTENDED RELEASE
RouteTRANSDERMAL
ModalitySmall molecule
FDA approvalSeptember 2014
Marketing statusRX

Listed patents

PatentExpiresType
8231906July 2030substance, product
9730900July 2028product
9833419July 2028product
9724310July 2028substance, product

More from Noven Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

MINIVELLE patent cliff — loss of exclusivity July 2030 | CliffBio